Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies

BACKGROUND: The efficacy and safety of ixekizumab (IXE) with and without continuous concomitant methotrexate (MTX), for up to 52 weeks of treatment, were evaluated in patients with active psoriatic arthritis (PsA). METHODS: Patients with active PsA who were biologic-naive (SPIRIT-P1) or had prior in...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Arthritis Res Ther
Egile Nagusiak: Combe, Bernard, Tsai, Tsen-Fang, Huffstutter, J. Eugene, Sprabery, Aubrey Trevelin, Lin, Chen-Yen, Park, So Young, Kronbergs, Andris, Hufford, Matthew M., Nash, Peter
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2021
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7839215/
https://ncbi.nlm.nih.gov/pubmed/33499913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-020-02388-5
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak